MedPath

Nitazoxanide

Generic Name
Nitazoxanide
Brand Names
Alinia, Busulfex
Drug Type
Small Molecule
Chemical Formula
C12H9N3O5S
CAS Number
55981-09-4
Unique Ingredient Identifier
SOA12P041N
Background

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .

Indication

用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions
Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
Associated Therapies
-

Nitazoxanide for Treatment of Cryptosporidium in Children

Phase 3
Not yet recruiting
Conditions
Cryptosporidiosis
Interventions
Drug: Nitazoxanide
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2024-12-24
Lead Sponsor
Johns Hopkins Bloomberg School of Public Health
Target Recruit Count
480
Registration Number
NCT06600711

Nitazoxanide in Patients With Metastatic Colorectal Cancer

Phase 3
Recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2023-09-22
Last Posted Date
2023-09-22
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT06049901
Locations
🇪🇬

Tanta University Hospital, Tanta, El-Gharbia Governorate, Egypt

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

Phase 2
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2023-08-25
Last Posted Date
2023-08-25
Lead Sponsor
Tanta University
Target Recruit Count
70
Registration Number
NCT06010992
Locations
🇪🇬

Faculty of medicine, Tanta University, Tanta, El-Gharbia, Egypt

🇪🇬

Faculty of Medicine, Menoufia University, Shibīn Al Kawm, Menoufia, Egypt

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Not Applicable
Completed
Conditions
Drug Interaction
Interventions
Drug: Nitazoxanide
Drug: Atazanavir/ritonavir
First Posted Date
2023-01-11
Last Posted Date
2023-09-13
Lead Sponsor
Obafemi Awolowo University
Target Recruit Count
17
Registration Number
NCT05680792
Locations
🇳🇬

Obafemi Awolowo University, Ile-Ife, Osun, Nigeria

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Phase 1
Completed
Conditions
Renal Impairment
Renal Disease
Kidney Disease
Interventions
First Posted Date
2022-05-10
Last Posted Date
2022-10-28
Lead Sponsor
Genfit
Target Recruit Count
77
Registration Number
NCT05368935
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Phase 3
Not yet recruiting
Conditions
COVID-19
Interventions
Drug: Nitazoxanide
Dietary Supplement: Vitamin Super-B Complex
Drug: Placebo
Other: Standard of Care
First Posted Date
2021-12-14
Last Posted Date
2023-09-29
Lead Sponsor
Romark Laboratories L.C.
Target Recruit Count
2000
Registration Number
NCT05157243

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Phase 3
Not yet recruiting
Conditions
COVID-19
Interventions
Drug: Placebo
Drug: Nitazoxanide
Dietary Supplement: Vitamin Super-B Complex
First Posted Date
2021-12-14
Last Posted Date
2023-09-29
Lead Sponsor
Romark Laboratories L.C.
Target Recruit Count
600
Registration Number
NCT05157269

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1
Completed
Conditions
Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases
Interventions
First Posted Date
2021-11-11
Last Posted Date
2022-10-14
Lead Sponsor
Genfit
Target Recruit Count
25
Registration Number
NCT05116826
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Phase 2
Recruiting
Conditions
COVID-19
Interventions
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Nitazoxanide
Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Hydroxychloroquine
Other: No treatment
Drug: Monoclonal antibodies
Drug: Fluoxetine
Drug: Molnupiravir
Drug: Sotrovimab
Drug: Ensitrelvir
Drug: Favipiravir
Drug: Ivermectin
Drug: Remdesivir
Drug: Atilotrelvir/ritonavir
Drug: Metformin
Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir
First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Favipiravir
Other: Nitazoxanide Placebo
Drug: Nitazoxanide
First Posted Date
2021-06-09
Last Posted Date
2023-03-24
Lead Sponsor
Coordinación de Investigación en Salud, Mexico
Target Recruit Count
120
Registration Number
NCT04918927
Locations
🇲🇽

Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico

© Copyright 2025. All Rights Reserved by MedPath